Precision for Medicine Accelerating Precision Oncology with Next Generation Screening to Support New Cancer Diagnostics
BETHESDA, MD — Nov. 3, 2022 — Precision for Medicine, the first biomarker-driven clinical research organization (CRO) supporting life sciences companies in the use of biomarkers essential to targeting patient treatments more precisely and effectively, announces the culmination of a groundbreaking Next Generation Sequencing (NGS) initiative which improved the accuracy and speed of identifying cancer mutations in solid tumors, allowing researchers and manufacturers to develop patient-specific diagnostics for improved clinical outcomes.
On-Demand: What’s Next for Cell and Gene Therapies in 2023 and Beyond
At this years Meeting on the Mesa’s conference, Anshul Mangal: President (Precision ADVANCE and Project Farma) sat down with leading industry experts to discuss the future of cell and gene therapies.
On-Demand: Overcoming Manufacturing Challenges for Advanced Medicines
Sponsored by Precision ADVANCE, this Endpoints webinar with convene leading advanced therapy experts to discuss manufacturing strategies for next-generation medicines. This discussion will be moderated by Adam Pfeiffer (VP of Strategy, Project Farma), and include insights from Charlie Harper (VP, Project Farma), Brian Stamper (VP of Cell Therapy Operations, Immunomic Therapeutics Inc.), Jim Watson (VP, Project Farma), Brian Riley (Chief Manufacturing Officer, Beam Therapeutics), and Chad Salisbury (SVP, Project Farma).
On-Demand: Gene Therapy Roundup—What to know now from the lab to the FDA
Gene therapy continues to evolve rapidly – from the science to the regulatory requirements. To give you a greater perspective on recent developments, this panel discussion brings together gene therapy experts across assay development, regulatory submissions, and clinical trial strategy who will share observations from the front lines on a multitude of gene therapy and rare disease projects.
Webinar: A Crisis in Rare Disease
There is a big need for therapeutic advancement in the rare disease community – however, public markets are stifling innovation and development for advanced medicines. This webinar, on Thursday, September 15th, will examine the current markets, their effect on the innovation in rare disease drug development, and what we can do to help.
Sponsored by Precision ADVANCE, this panel features insights from industry leaders on their organization’s pipeline, the advanced therapy investment landscape, and the innovation, manufacturing, and community needs to successfully bring an advanced therapy to market. This discussion will be moderated by Anshul Mangal (President, Project Farma & Precision ADVANCE), and include insights from Alex Karnal (Founder, Braidwell), Chidozie Ugwumba (Managing Partner, Symbiosis), James Wilson (Director, Perelman School of Medicine, UPenn), and Tony Khoury (EVP, Project Farma).
Key points to be discussed:
- Learn about the current state of investments for the rare disease sector
- Understand the market’s effect on innovation in rare disease
- Hear from leading experts on what we do as a community to help drive innovation forward